Actively Recruiting
Evaluation of Membrane Phospholipid and Energy Metabolism in Subjects at High Risk of Psychotic Transition
Led by Centre Hospitalier Henri Laborit · Updated on 2026-01-13
22
Participants Needed
1
Research Sites
156 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The management of schizophrenia is a major public health issue, due to its particularly disabling psychotic symptoms and their onset at an early age, typically in adolescents or young adults. The physiopathological hypothesis of an anomaly relating to the renewal of cell membranes and energy metabolism in schizophrenia was proposed as early as the 1930s. This is based on anomalies at certain times in the development of the balance between phosphomonesters, precursors of membrane phospholipids, and phosphodiesters, catabolites of membrane phospholipids. Alterations of these different balances sign neurodevelopmental disorders, and can be objectified by specific techniques such as phosphorus-31 magnetic resonance spectroscopy (SMR-31P). This is used in particular to characterize the energy metabolism of the brain and allows in vivo quantification of phosphorus metabolites. The application of SMR-31P techniques to assess the metabolism of membrane phospholipids and cellular energy metabolism in subjects at high risk of psychotic transition could make it possible to objectify a difference between subjects subsequently suffering from a psychotic transition compared to those who do not suffer from it. Alterations in the metabolism of membrane phospholipids could thus represent a biomarker of psychotic transition. Secondarily, this approach would make it possible to provide elements as to the validity as a diagnosis of this category, which is very heterogeneous in its future. Among the Ultra High Risk (UHR) group, subjects with a psychotic transition (UHR-T) are compared to subjects without this transition (UHR-NT) during the two years of follow-up. The UHR group is compared to the control group. At T0, UHR patients and healthy volunteers will perform brain MRI with Phosphorus 31 magnetic resonance spectroscopy. UHR patients will then be reviewed: * at T+1 year for a clinical assessment medical interview to assess the patient's functioning and the appearance of symptoms; * at T+2 years for the realization of a follow-up interview with passing of the scales CAARMS (Comprehensive Assessment of At Risk Mental State) and SOFAS (scale of evaluation of the social and professional functioning) in order to determine if the subject belongs to the UHR-T or UHR-NT group.
CONDITIONS
Official Title
Evaluation of Membrane Phospholipid and Energy Metabolism in Subjects at High Risk of Psychotic Transition
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participant aged between 15 and 25 years old
- Meets Ultra High Risk criteria for psychotic transition based on CAARMS and SOFAS scales or belongs to the "Vulnerability" group combining family history and functional impact
- No contraindications to 7T MRI examination
- Affiliated with or beneficiary of a social security scheme
- Provides free, informed, written consent signed by participant, investigator, and legal representative if applicable
- Healthy volunteers aged 15 to 25 years without mental health disorder for the control group
- Control subjects with no contraindications to 7T MRI
- Control subjects affiliated with or beneficiaries of a social security scheme
- Control subjects provide free, informed, written consent signed by participant, investigator, and legal representative if applicable
You will not qualify if you...
- Not at risk or already diagnosed with a psychotic disorder according to DSM-5 criteria
- Currently receiving antipsychotic treatment or treatment changed less than one month ago
- Absolute contraindications to 7T MRI such as intracranial clips, pacemakers, stents, cochlear implants, metallic fragments, mechanical heart valves, implanted pumps, non-removable piercings
- Pregnancy, breastfeeding, or implanted contraception
- Allergy to contrast products
- Moderate to severe kidney failure
- Claustrophobia, tinnitus, or braces
- Relative contraindications to MRI including previous surgeries, implanted medical devices, tattoos, or permanent makeup
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Centre Hospitalier Henri Laborit
Poitiers, France, 86000
Actively Recruiting
Research Team
R
Richard HARY
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
DIAGNOSTIC
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here